NASDAQ:TNDMTandem Diabetes Care Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tandem Diabetes Care Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $104.15 -1.35 (-1.28 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$102.71Now: $104.15▼$108.7650-Day Range$84.94MA: $98.22▼$107.7552-Week Range$43.69Now: $104.15▼$110.80Volume798,236 shsAverage Volume815,534 shsMarket Capitalization$6.34 billionP/E RatioN/ADividend YieldN/ABeta0.56 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $111.62, Tandem Diabetes Care has a potential upside of 7.2% from its current price of $104.15.Amount of Analyst CoverageTandem Diabetes Care has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesTandem Diabetes Care has received 527 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTandem Diabetes Care has received 520 “underperform” votes. (Add your “underperform” vote.)Community SentimentTandem Diabetes Care has received 50.33% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote “Outperform” if you believe TNDM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,973,242.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of Tandem Diabetes Care is held by insiders.Percentage Held by Institutions91.73% of the stock of Tandem Diabetes Care is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -138.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -138.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 23.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM Previous Symbol CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone858-366-6900Debt Debt-to-Equity Ratio0.80 Current Ratio4.72 Quick Ratio4.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$362.30 million Price / Sales17.51 Cash FlowN/A Price / Cash FlowN/A Book Value$4.40 per share Price / Book23.67Profitability EPS (Most Recent Fiscal Year)($0.22) Net Income$-24,750,000.00 Net Margins-10.29% Return on Equity-12.88% Return on Assets-6.83%Miscellaneous Employees1,043 Outstanding Shares60,910,000Market Cap$6.34 billion Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $104.15 -1.35 (-1.28 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TNDM News and Ratings via Email Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions How has Tandem Diabetes Care's stock been impacted by COVID-19 (Coronavirus)? Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TNDM stock has increased by 57.0% and is now trading at $104.15. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tandem Diabetes Care? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tandem Diabetes Care. When is Tandem Diabetes Care's next earnings date? Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Tandem Diabetes Care. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care Inc (NASDAQ:TNDM) issued its quarterly earnings data on Thursday, July, 30th. The medical device company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.21. The medical device company had revenue of $109.24 million for the quarter, compared to analysts' expectations of $86.51 million. Tandem Diabetes Care had a negative net margin of 10.29% and a negative return on equity of 12.88%. View Tandem Diabetes Care's earnings history. When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work? Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care updated its FY 2020 After-Hours earnings guidance on Thursday, July, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450-465 million, compared to the consensus revenue estimate of $417.24 million. What price target have analysts set for TNDM? 13 equities research analysts have issued 12 month target prices for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $140.00. On average, they expect Tandem Diabetes Care's stock price to reach $111.62 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View analysts' price targets for Tandem Diabetes Care. Has Tandem Diabetes Care been receiving favorable news coverage? Headlines about TNDM stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tandem Diabetes Care earned a coverage optimism score of -4.8 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Tandem Diabetes Care. Are investors shorting Tandem Diabetes Care? Tandem Diabetes Care saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 3,520,000 shares, a drop of 7.4% from the July 15th total of 3,800,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is presently 2.8 days. Approximately 6.1% of the company's shares are sold short. View Tandem Diabetes Care's Short Interest. Who are some of Tandem Diabetes Care's key competitors? Some companies that are related to Tandem Diabetes Care include ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), Insulet (PODD), Penumbra (PEN), Novocure (NVCR), Hill-Rom (HRC), Globus Medical (GMED), Irhythm Technologies (IRTC), Nevro (NVRO), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI), Inovio Pharmaceuticals (INO) and Inari Medical (NARI). View all competitors. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Roku (ROKU). Who are Tandem Diabetes Care's key executives? Tandem Diabetes Care's management team includes the following people: Mr. Kim D. Blickenstaff, Exec. Chairman (Age 67)Mr. John F. Sheridan, Pres & CEO (Age 64)Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)Mr. Manuel Jaime, Sr. VP of Technology & Digital Health What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (15.38%), TimesSquare Capital Management LLC (1.37%), Columbus Circle Investors (1.10%), Ardevora Asset Management LLP (0.98%), Jennison Associates LLC (0.75%) and New York State Common Retirement Fund (0.46%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View institutional ownership trends for Tandem Diabetes Care. Which institutional investors are selling Tandem Diabetes Care stock? TNDM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Ardevora Asset Management LLP, TimesSquare Capital Management LLC, Russell Investments Group Ltd., Hodges Capital Management Inc., Frontier Capital Management Co. LLC, Strs Ohio, and UBS Group AG. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, and Susan Morrison. View insider buying and selling activity for Tandem Diabetes Care. Which institutional investors are buying Tandem Diabetes Care stock? TNDM stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, SeaTown Holdings Pte. Ltd., Columbus Circle Investors, New York State Common Retirement Fund, Ziegler Capital Management LLC, State Board of Administration of Florida Retirement System, Candriam Luxembourg S.C.A., and Swiss National Bank. View insider buying and selling activity for Tandem Diabetes Care. How do I buy shares of Tandem Diabetes Care? Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $104.15. How big of a company is Tandem Diabetes Care? Tandem Diabetes Care has a market capitalization of $6.34 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe. What is Tandem Diabetes Care's official website? The official website for Tandem Diabetes Care is www.tandemdiabetes.com. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
